SEC Form 4 · accession 0001193125-26-295059
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dennis A Ausiello
Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 6:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001609809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.94 | Jul 1, 2026 | A | 7,508 | A | — | Jul 1, 2036 | Common Stock | 7,508 | 7,508 | D |
Explanation of responses
- F1The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, provided that if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date.